Inicio・Lista de Acciones・Viking Therapeutics Inc

Viking Therapeutics Inc

Cerrado

SectorSanidad

32.81 0.71

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

32.47

Máximo

33.51

Métricas clave
By Trading Economics
Ingresos	30M -128M
BPA	-1.1
Empleados	65
EBITDA	30M -128M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+182.37% upside

Dividendos
By Acuity
Próximas Ganancias	21 oct 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-245M 3.8B
Apertura anterior	32.1
Cierre anterior	32.81

Noticias sobre sentimiento de mercado

By Acuity

50%

175 / 340 Clasificación en Healthcare

Viking Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

4 ago 2026, 23:02 UTC

Social Media

Viking Therapeutics Inc shares are lower in after-market hours amid routine trading. The stock remains below its 20-day moving average.

3 ago 2026, 23:06 UTC

Viking Therapeutics shares are higher in after-market trading, reflecting positive sentiment from stronger-than-expected manufacturing PMI data indicating sector growth.

31 jul 2026, 23:51 UTC

Viking Therapeutics Inc is higher in after-market trading, recovering from earlier session lows after four consecutive declines. The stock remains below its 20-day moving average.

30 jul 2026, 23:56 UTC

News

Viking Therapeutics Inc. shows a modest gain in after-market hours amid a wave of biopharmaceutical mergers, including Vertex's $10 billion acquisition of Crinetics.

29 jul 2026, 23:21 UTC

Social Media

News

Viking Therapeutics reported a Q2 loss of $1.10 per share, better than expected. The company highlighted progress in its obesity treatment pipeline.

28 jul 2026, 23:11 UTC

News

Viking Therapeutics shares are lower in after-market hours amid ongoing challenges and a significant decline over the past two years. Analysts maintain a bullish outlook.

27 jul 2026, 23:56 UTC

Viking Therapeutics Inc shares are lower in after-market hours, reflecting a lack of specific news and remaining below the 20-day moving average.

25 jul 2026, 00:01 UTC

Viking Therapeutics Inc shares are lower in after-market trading, continuing a trend of four consecutive sessions finishing down. No specific news was identified.

24 jul 2026, 21:01 UTC

Viking Therapeutics Inc. is higher in after-market trading, reversing recent losses despite no specific news driving the price movement.

23 jul 2026, 23:46 UTC

Event

Viking Therapeutics shares are higher in after-market trading ahead of Q2 earnings, with estimated EPS of -$1.21, up from -$0.58.

22 jul 2026, 23:36 UTC

Viking Therapeutics Inc. shares showed little change during after-market hours, trading within a narrow range and settling near unchanged levels.

Comparación entre iguales

Cambio de precio

Viking Therapeutics Inc previsión

Precio Objetivo

By TipRanks

182.37% repunte

Estimación a 12 Meses

Media 92.08 USD 182.37%

Máximo 114 USD

Mínimo 70 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Viking Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

14 ratings

Comprar

Mantener

Vender

De acuerdo con 14 analistas que ofrecen calificaciones bursátiles a para Viking Therapeutics Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

175 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.